Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007


On April 19, 2007 Shire completed its acquisition of New River by way of a short-form merger, in an all-cash transaction. The acquisition was effected by merging Shuttle Corporation, an indirect wholly owned subsidiary of Shire, with and into New River, with New River continuing as the surviving corporation. As consideration, Shire paid to New River's shareholders US$64 in cash for each share of New River common stock outstanding at the time of the acquisition.

The acquisition of New River allows Shire to capture the full economic value of VYVANSE, and gain control of the future development and commercialisation of this product.

VYVANSE for ADHD in paediatric patients was approved by the FDA on February 23, 2007 and Shire received notification from the DEA of the final Schedule II classification for VYVANSE on May 3, 2007.

The acquisition of New River has been accounted for as a purchase business combination in accordance with IFRS 3. Under the purchase method of accounting, the assets and liabilities of New River are recorded at their fair values at the acquisition date. The financial statements of Shire issued after the completion of the acquisition reflect these fair values, with the results of New River being included within the Consolidated Income Statement from April 19, 2007.

Total consideration, including amounts payable in respect of stock options, share appreciation rights ("SARs"), warrants over New River's common stock and costs directly attributable to the business combination was approximately US$2.6 billion at the price of US$64 per share of New River's common stock, as analysed below:



Cash consideration for 37.1 million outstanding shares of New

River common stock at US$64 per share (net of 1.5 million of

common stock repur

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
(Date:7/28/2015)... -- Faced with increasing challenges such as costly treatments ... the global healthcare industry today is gradually transforming ... or significantly changing the course of a disease, ... medicine as a viable alternative. Regenerative ... with the potential to resolve unmet medical needs ...
(Date:7/27/2015)... 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ... commercializing products for the treatment of cancer, today provides ... it has closed a $1,000,000 unit offering private placement.  ... units of the Company at a price of $0.06 ... share and one common share purchase warrant.  Each whole ...
(Date:7/27/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader ... Ways to GHS Labels . This video provides useful information on how to ... effectively labeling chemical containers. , “With the fourth and final deadline for HazCom/GHS ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced ... The venture will bring the world’s most efficient gas dissolution technology to all ... technologies to both the industrial and municipal markets. With offices located in Sarasota, ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2BlueInGreen Brings Water Treatment Technology to Florida 2
... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... therapies, today announced that it will hold a ... and year-end financial results and provide a corporate ... Company,s lead product candidate.Jerry McMahon, Ph.D., chairman and ...
... NEW YORK, March 5 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... a letter from the Staff of The Nasdaq Stock ... compliance with Nasdaq Marketplace Rule 4310(c)(3), which requires the ... equity, or $35,000,000 market value of listed securities, or ...
... March 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... company focused on researching,developing, manufacturing and marketing ... the relevant provisions issued by the,Office of ... Finance,National Revenue Department in Liaoning Province and ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... growth of several types of cancer cells lead to ... at Winship Cancer Institute of Emory University have discovered. ... that cancer cells tend to consume more glucose, or ... as the "Warburg effect," honoring discoverer Otto Warburg, a ...
... Like other users of microfluidic systems, National Institute ... faced with an annoying engineering problem: how to simply, ... devices to the external pumps and reservoirs delivering liquids ... randomly picked up two magnets and began playing with ...
... moa, a giant extinct bird, has revealed a new geological ... in the Proceedings of the National Academy of Sciences ... University of Adelaide has reconstructed a history of marine barriers, ... of years, using the first complete genetic history of the ...
Cached Biology News:Cancers' sweet tooth may be weakness 2Novel NIST connector uses magnets for leak-free microfluidic devices 2Extinct moa rewrites New Zealand's history 2
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
Biology Products: